⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66814 | 1.00 | — | — | |
| SCHEMBL27583923 | 0.80 | RIPK1 (0.45) | — | |
| SCHEMBL212732 | 0.72 | — | — | |
| SCHEMBL29580420 | 0.72 | — | — | |
| SCHEMBL687180 | 0.72 | KDM4E (0.55) | — | |
| SCHEMBL29769309 | 0.72 | KDM4E (0.55) | — | |
| SCHEMBL29366238 | 0.72 | — | — | |
| SCHEMBL103661 | 0.72 | — | — | |
| Calcium SCHEMBL38655972 | 0.70 | — | — | |
| SCHEMBL31088692 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245003-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4642451-A2 | N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025096589-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4536656-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4522620-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | Admare Therapeutics Society (CA) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024145273-A2 | N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE | SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024033280-A1 | FUROPYRIDIN AND FUROPYRIMIDIN, INHIBITORS OF PI4K, FOR USE IN THE TREATMENT OF PARASITE INFECTION AND MALARIA | MERCK PATENT GMBH (DE) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023215991-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | adMare Therapeutics Society (CA) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023121713-A1 | BCL-2 INHIBITORS | NEW AVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023009708-A1 | HETEROARYLOXY TRIAZOLO- AND IMIDAZO-AZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022204150-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |